Merck announced on January 31, 2025, that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended the approval of CAPVAXIVE (Pneumococcal 21-valent Conjugate Vaccine). This recommendation is for active immunization for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae in individuals 18 years of age and older.
The CHMP's recommendation will now be reviewed by the European Commission (EC) for marketing authorization in the European Union (EU), Iceland, Liechtenstein, and Norway, with a final decision expected by the second quarter of 2025. This positive opinion is a testament to the clinical profile of CAPVAXIVE.
CAPVAXIVE is specifically designed to protect adults against serotypes predominantly responsible for invasive pneumococcal disease. This development brings Merck closer to helping protect adults in the EU against this critical public health challenge, expanding its global vaccine footprint.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.